Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.

@article{Greenberg1997InitialRO,
  title={Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.},
  author={Richard Evan Greenberg and Robert R. Bahnson and David Wood and Stacy J Childs and Catherine M Bellingham and Mitchell Edson and Mitchell H Bamberger and Gary D. Steinberg and Mervyn Israel and Trevor Sweatman and Bruce J. Giantonio and Patrick J O'Dwyer},
  journal={Urology},
  year={1997},
  volume={49 3},
  pages={471-5}
}
OBJECTIVES This study was designed to assess the pharmacokinetics, safety, and antitumor activity of intravesically administered AD 32, a novel anthracycline, in patients with transitional cell carcinoma (TCC) of the bladder. METHODS Six weekly doses of AD 32 (200 to 900 mg) were administered to 32 patients with superficial TCC who were candidates for intravesical treatment. Serum drug levels were measured during the 6-hour period after administration of the first, third, and sixth doses… CONTINUE READING